Signal transducer and activator of transcription 3 activation is associated with bladder cancer cell growth and survival
- Chun-Liang Chen1, 2,
- Ling Cen3,
- Jennifer Kohout4,
- Brian Hutzen5,
- Christina Chan2, 2,
- Fu-Chuan Hsieh1, 2,
- Abbey Loy,
- Victor Huang1, 2,
- Gong Cheng1, 2 and
- Jiayuh Lin1, 2, 3, 4, 5Email author
© Chen et al; licensee BioMed Central Ltd. 2008
Received: 25 September 2007
Accepted: 21 October 2008
Published: 21 October 2008
Constitutive activation of signal transducer and activator of transcription 3 (Stat3) signaling pathway plays an important role in several human cancers. Activation of Stat3 is dependent on the phosphorylation at the tyrosine residue 705 by upstream kinases and subsequent nuclear translocation after dimerization. It remains unclear whether oncogenic Stat3 signaling pathway is involved in the oncogenesis of bladder cancer.
We found that elevated Stat3 phosphorylation in 19 of 100 (19%) bladder cancer tissues as well as bladder cancer cell lines, WH, UMUC-3 and 253J. To explore whether Stat3 activation is associated with cell growth and survival of bladder cancer, we targeted the Stat3 signaling pathway in bladder cancer cells using an adenovirus-mediated dominant-negative Stat3 (Y705F) and a small molecule compound, STA-21. Both prohibited cell growth and induction of apoptosis in these bladder cancer cell lines but not in normal bladder smooth muscle cell (BdSMC). The survival inhibition might be mediated through apoptotic caspase 3, 8 and 9 pathways. Moreover, down-regulation of anti-apoptotic genes (Bcl-2, Bcl-xL and survivin) and a cell cycle regulating gene (cyclin D1) was associated with the cell growth inhibition and apoptosis.
These results indicated that activation of Stat3 is crucial for bladder cancer cell growth and survival. Therefore, interference of Stat3 signaling pathway emerges as a potential therapeutic approach for bladder cancer.
bladder smooth muscle cell
[3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide]
protein inhibitors of activated STATs
SH2-containing tyrosine phosphotases
signal transducer and activator of transcription 3.
Several malignancies have been shown to result from constitutive activation of STATs, in particular Stat3 and 5 [1, 2]. Stat3 is widely expressed in normal tissues and transiently activated and then inactivated by a group of signaling proteins, such as SH2-containing tyrosine phosphotases (SHP1 and SHP2), protein inhibitors of activated STATs (PIAS) and suppressor of cytokine signaling proteins/extracellular signaling regulated kinase (SOCS/ERK) cascades [3–5]. In a variety of human cancers, defects in these signaling pathways or persistent presence of up-stream activators would lead to constitutive activation of Stat3 and tumorgenesis [6, 7]. Interference of constitutive Stat3 signaling pathway suppresses chemotherapy resistance, tumor growth and metastasis, induces cancer cell death and therefore shows great potential for cancer therapy [8, 9].
Several lines of evidence suggest that constitutive activation of Stat3 might play a role in bladder malignancy. Bladder cancer is one of the common malignancies and molecular causes for its progress and development have been intensively investigated [10–12]. However, the detailed picture of oncogenic pathways for bladder cancer has just begun to be revealed . Bladder cancer is induced by amplification of oncogenes [eg. fibroblast growth factor receptor 3 (FGFR3) and Ras gene] or by mutational defects in tumor suppressor genes (eg. PTCH & PTEN). These diverse genetic changes lead to oncogenic signalings via MAPK, PI-3 kinase, AKT and c-Myc pathways. Overactive FGFR3 and ERBB2 in bladder cancer presumably would activate Stat3 that is down-stream to these two receptor tyrosine kinases . Another line of evidence is that overexpression of Stat3-regulated anti-apoptotic genes (Bcl-2, Bcl-xL and survivin) is found in bladder cancer. Overexpression of these genes renders bladder cancer progression, accelerated rates of recurrences, anti-apoptosis and chemotherapeutic resistance [13–18]. The role of activated Stat3 in bladder cancer remained speculative until the recent report showed that Stat3 activation correlated with malignant characteristics of T24 bladder cancer cells . This implicates that activation of Stat3 may play a role in the development of bladder cancer.
We initiated a study to explore any further relation between activation of Stat3 and bladder malignancy. We found that 19 of 100 (19%) bladder cancer biopsy tissues had elevated expression of phosphorylated-Stat3 (p-Stat3) using an immunohistochemical staining with a p-Stat3 specific monoclonal antibody. In addition, elevated p-Stat3 expression was also found in bladder cancer cell lines, UMUC-3, 253J and WH. Thereafter, we targeted the activated Stat3 signal pathway using a dominant negative Stat3 Y705F (dnStat3) and a small molecule inhibitor, STA-21 [8, 20]. Inhibition of Stat3 pathway suppressed cell growth of bladder cancer cells in vitro. DnStat3 and STA-21 also induced apoptosis as revealed by immunostaining of cleaved caspases 3, 8 and 9 in bladder cancer cells. Down regulation of anti-apoptotic genes (Bcl-2, Bcl-xL and survivin) and a cell-cycle regulating gene, cyclin D1, were correlated with dnStat3- and STA-21 induced apoptosis and cell growth inhibition. Taken together, Stat3 activation may play a pivotal role in bladder cancer cell growth and survival and serve as a novel therapeutic target for this type of cancer.
p-Stat3 was elevated in bladder cancer tissues
Clinicopathological parameters of urinary bladder cancers used
Stage (total 45)
Grade (Total 57)
Regional lymph node and/or distant metastasis
Histology (total 54)
Squamous cell carcinoma
p-Stat3 was also elevated in bladder cancer cell lines
rAd-mediated transduction of dnStat3 in bladder cancer cell lines
Targeting Stat3 signaling pathway using dnStat3 and STA-21 induced cell growth and viability inhibition in bladder cancer cells
As MTT assay showed, similar inhibition on cell growth and viability was observed in bladder cancer cells treated with 30 μM STA-21 (Figure 4C). Viability of bladder cancer cells and BdSMC treated with DMSO was about the same as untreated controls. However, exposure to STA-21 greatly reduced cell viability of 253J, UMUC3 and WH (38.1 ± 0.74%, 11.4 ± 1.5%, and 29.0 ± 6.7%). Interestingly, STA-21 had very minimal effects on BdSMC cell viability (91.3 ± 4.4%). This indicated that STA-21 inhibition is specific to bladder cancer cells that have constitutive activation of Stat3. In addition, the decreased overall viability of cells treated with STA-21 was consistent with that observed in cells treated with rAd/dnStat3. These together suggested that bladder cancer cell death associated with inhibition of Stat3 pathway might have occurred.
Inhibition of Stat3 pathway induces activation of apoptotic caspase pathways
Targeting Stat3 pathway using STA-21 also led to increased cleavage of caspase 3 after 72 hours of treatment in 253J, UMUC-3 and WH (Figure 5C and data not shown). About 6.4–13% cells were cleaved caspase 3 positive in these three STA-21-treated bladder cancer cell lines, compared to less than 0.5% in untreated or DMSO-treated cells. STAT-21 treatment did not seem to induce caspase 3 cleavage in BdSMC cells with less than 0.1% appearing positive with anti cleaved caspase 3 immunoreactivity. The increased apoptotic caspase activation implicated that apoptosis could be one of mechanisms underlying the decreased cell viability in bladder cancer cells in that Stat3 pathway was compromised by treatment of rAd/Stat3 or STA-21.
dnStat3 down-regulated anti-apoptotic genes and cyclin D1 in bladder cancer cells
We also examined the expression of anti-apoptotic genes and cyclin D1 in WH bladder cancer cells when Stat3 pathway was targeted by rAd/dnStat3 or STA-21. Mcl-1 (80% untreated control) was apparently not affected as compared with the control treated with rAd/eGFP but Bcl-2 (16.6%) and Bcl-xL (46.9%) protein expressions were down regulated by the transduction of dnStat3 (Figure 6B). In addition, cyclin D1 expression (1.9% untreated control) was almost completely inhibited by the interference of Stat3 signaling pathway. Expression reduction in two anti-apoptosis genes (Bcl-2 and Bcl-xL) and cyclin D1 were consistent with apoptosis and cell growth inhibition in WH cells. Four days of treatment of STA-21 showed similar but less reduction in survivin (19.6% untreated control), Bcl-2 (64%) and Bcl-xL (79.2%) expressions.
Constitutive activation of Stat3 signaling pathway is frequently detected in several types of human cancers. This report was to explore the correlation between bladder cancer and Stat3 status in bladder cancer tissues and cell lines. We found that elevated p-Stat3 expression is found in both bladder cancer tissues and cell lines. Among 100 primary bladder cancer biopsy tissues, 19% appears positive in p-Stat3 immunostaining in nuclei, cytoplasm or both compartments. Majorities of bladder cancer tissues examined are negative for p-Stat3 and may result from other causes for this kind of cancer . Elevated p-Stat3 expression is also found in bladder cancer cells, UMUC-3, WH and T24. These suggest that elevated p-Stat3 might contribute to some of bladder malignancy. Phosphorylation at tyrosine 705 is required for the activation of Stat3. Elevated Stat3 phosphorylation in these bladder tissues and cell lines might result from abnormal overactive upstream oncogenic FGFR or ERBB2 in these cancer tissues [10, 21]. A recent study shows that overactive Stat3 serves as the signal mediator between EGF and MMP-1 for bladder cancer cell migration, invasion and tumor formation . Alternative explanation is the down regulation of counter balancing signal transduction pathways, such as SH2-containing tyrosine phosphotase (SHP1 and 2), protein inhibitors of activated Stats (PIAS), and suppressors of cytokine signaling (SOCS), could also contribute to higher Stat3 phosphorylation in these bladder cancer tissues or cell lines . These need further verifications using tissue microarray immunohistochemistry or quantitative PCR.
Our data suggest that bladder cancer cells might utilize Stat3 signaling pathway for cell growth and survival. Interruption of Stat3 pathway using a dnStat3 or STA-21 affects bladder cancer cell growth and induces the activation of apoptotic caspases. DnStat3 may inhibit phosphorylation and dimerization of endogenous Stat3 [22–24] and down regulates a group of survival and proliferation genes [25–27]. STA-21 was discovered from a virtual drug screen and showed efficacy in blocking Stat3 dimerization and translocation into nuclear compartments . Our data, consistent with previous studies, has delineated part of the relationship between elevated p-Stat3 expression and bladder cancer , although mechanisms for cell growth inhibition and cell death by dnStat3 in bladder cancer cell UMUC-3 and WH remain largely unclear. Reduction of cyclin-D1 expression in WH and UMUC-3 cells might be part of the causes for cell growth inhibition. This is consistent with previous study that targeting Stat3 signaling with dnStat3 suppresses cell-cycle-related genes, including cyclin-D1, in ALK-positive anaplastic large cell lymphoma .
Interruption of Stat3 pathway by dnStat3 and STA-21 leads to activation of caspase 3 signaling in bladder cancer cells. Apparently, dnStat3-induced cleavage of caspase 3 is also mediated through caspases 8 and 9 pathways. Caspases 8 and 9 are key initiator caspases for two largely independent apoptotic pathways mediated by death receptors and stresses [29–32]. Cleaved caspase 8 suggests an autocrine signal(s) following dnStat3 transduction in bladder cancer cells. Fas, TRAIL receptors and their ligands are usually suppressed in several cancers to prevent apoptosis [33, 34]. Stat3 has been shown to directly down regulate Fas, TRAIL, and TGF-α [35–37]. To Target Stat3 signaling pathway using Stat3β upregulates TRAIL and a secretory apoptotic signal(s) in B16 tumor cells. What death receptor(s) is involved in dnStat3-induced apoptosis in bladder cancer cells acquires further investigations.
Activation of caspase 9 pathway in bladder cancer cells is very likely triggered by down regulation of Bcl-2 family genes and inhibitors of apoptotic proteins (IAP). We observed that two Bcl-2 family genes (Bcl-2 and Bcl-xL) and an IAP gene (survivin) are negatively affected at protein level by dnStat3 and STA-21. Overexpression of Bcl-2, Bcl-xL, and survivin in several cancers overcomes severe tumor environments and facilitates cancer progression, chemotherapeutic resistance and higher rate of recurrence [15, 17, 18, 38, 39]. Down regulation of these genes likely contributes to the dnStat3- and STA-21-induced activation of apoptotic caspases in bladder cancer cells. DnStat3 also inhibits Stat3 signaling in ALK-positive anaplastic large cell lymphoma by suppression of several Bcl-2 family genes . Activated Stat3 promoting cancer survival and proliferation has been demonstrated in several cancers [8, 40–48]. To suppress Stat3 signaling pathway using anti-sense RNA, siRNA, small molecules, decoy-oligos and dnStat3 results in cancer cell growth inhibition and apoptosis. It appears that targeting dnStat3 signaling pathway could be an effective therapeutic approach for bladder cancer expressing constitutive activation of Stat3.
Our data show that Stat3 phosphorylation is elevated and may play a pivotal role in cell growth and survival of bladder cancer. Cell growth inhibition and apoptosis can be induced in bladder cancer cell lines using either a dnStat3 or a small molecule inhibitor, STA-21 to interfere with the Stat3 signaling pathway. The Stat3 signaling pathway appears as a potential target for bladder cancer therapy.
Bladder cancer cell lines were purchased from American Type Culture Collection (ATCC). Cell lines were maintained in 1× DMEM supplemented with 10% fetal bovine serum and 100 U/ml penicilin/streptomycin/amphotericin B (Mediatech, Herndon, VA) at 37°C, aired with 5% CO2. Bladder smooth muscle cells (BdSMC) were purchased from Cambrex Bio Science and maintained in SmGM®-2-Smooth muscle medium (Cambrex, Chicago, IL) supplemented with 5% FBS.
Bladder cancer tissue microarray immunohistochemistry
Stat3 phosphorylation status in bladder cancer tissues were examined using immunohistochemistry with a p-Stat3 (Y705)-specific monoclonal antibody (Cell Signaling Tech., Danvers, MA). We stained bladder cancer tissue samples (n = 102) on tissue microarray slides from two different providers (US Biomax, Inc., Rockville, MD and ISU ABXIS Co., Seoul, Korea). The immunohistochemistry and scoring of p-Stat3 expression were described previously . Most of the p-Stat3 positive cancer tissues showed staining in greater than 50% of each sample.
Western blots were carried out according to protocols described previously . 10 to 100 μg of cellular proteins were resolved on 10% or 14% SDS-PAGE gels before transfer, immunoblotting, and visualization of specific protein bands. Antibodies were purchased separately and used to recognize FLAG (Sigma, St. Louis, MO) GAPDH (Chemicon International, Temecula, CA). Stat3, p-Stat3 (Y705) (Cell Signaling Tech., Danvers, MA), Bcl-2, Bcl-xL (Biosciences, Inc. Franklin Lakes, NJ,), Mcl-1, cyclin D1 (Lab Vision Corp., Fremont, CA) and survivin (UpState, Charlotteville, VG)
For expression comparison, each protein expression was presented in a percentage of its corresponding untreated control after densitometric quantification and normalization to the GAPDH expression. A representative one from duplicated experiments was presented.
Transduction of dnStat3 in bladder cancer cell lines
The construction of recombinant Adenovirus/CMV-dnStat3 Y705F (rAd/dnStat3) is described previously . DnStat3 was generated from Stat3 by changing the tyrosine at position 705 into phenylalanine. The dnStat3 protein product is tagged with a 6-repeat FLAG sequence for detection and cannot be activated through tyrosine phosphorylation. About 2 × 105 WH and UMUC-3 cells were transduced with rAd/dnStat3 or rAd/CMV-eGFP (rAd/eGFP) (Applied Viromics, Fremont, CA) at variant multiplicities of infection (moi) based on TCID50 assay using 293T cells. For cell growth experiments, cell numbers were enumerated at day 2 or 4 post-infection. Cell counts in 5 random fields of view (magnification 100×) were obtained for each treatment and control. Cell growth rates were presented in percentages of cell density of untreated controls and averaged from triplicate experiments.
Treatment of STA-21 and Cell viability assay
Approximately 5000 cells were grown in 100 μl 10% FBS-supplemented DMEM medium in 96-well flat-bottomed plates overnight. Cells were exposed to STA-21 (30 μM) that was dissolved in dimethyl sulfoxide (DMSO) before added to the medium. Cell viability was analyzed by the MTT [3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide] (Sigma) assay in three replicates. At the time of assay end-point, cells were treated with MTT (1 mg/ml) for 3–4 hours. Colormetric quntitation was determined by an EL808 Ultra Microplate Reader (Bio-Tek Intruments, Inc) after formazan was dissolved in 25% N, N-dimethylformamide and 10% SDS in a light-proof condition overnight.
Caspases 3, 8, and 9 immuno-fluorescent staining
Approximately 1 or 2 × 105 cells (UMUC-3, WH, 253J, and BdSMC) were seeded on sterile coverslips in a 6-well plate overnight, either transduced by either rAd/eGFP or rAd/dnStat3 (moi = 500) for 48 or 28 hours respectively, for UMUC-3 and WH cells. For the small molecule inhibition, cells were treated with 30 μM STA-21 for 72 hours. Cleaved caspase immunostaining and documentation were described previously . The primary rabbit antibodies were diluted with 1:100, 1:50, and 1:100 dilutions, respectively, for detecting cleaved-caspase-3 (Asp175), cleaved-caspase-8 (Asp374), or cleaved-caspase-9 (Asp330) (Cell Signaling Tech)
This work was supported in part by a start-up fund from the Center for Childhood Cancer, The Research Institute at Nationwide Children's Hospital, Department of Pediatrics at the Ohio State University, a NCI grant (RO1 CA096714) and a Susan G. Koman Breast Cancer Foundation grant to J. Lin. Thanks to Jason Canner for carefully reading this manuscript and valuable comments.
- Bowman T, Garcia R, Turkson J, Jove R: STATs in Oncogenesis. Oncogene. 2000, 19: 2474-2488.View ArticlePubMed
- Garcia R, Yu C, Hudnall A, Catlett R, Nelson K, Smithgall T, Fujita D, Ethier S, Jove R: Constitutive Activation of STAT 3 in Fibroblasts Transformed by Diverse Oncoproteins and in Breast Carcinoma Cells. Cell Growth Differ. 1997, 8: 1267-1275.PubMed
- Chen CL, Hsieh FC, Lin J: Systemic evaluation of total Stat3 and Stat3 tyrosine phosphorylation in normal human tissues. Exp Mol Pathol. 2006, 80: 295-305.View ArticlePubMed
- Kamimura D, Ishihara K, Hirano T: IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev Physiol Biochem Pharmacol. 2003, 149: 1-38.View ArticlePubMed
- Valentino L, Pierre J: JAK/STAT signal transduction: Regulators and implication in hematological malignancies. Biochem Pharmacol. 2006, 71: 713-721.View ArticlePubMed
- Bromberg J, Wrzeszczynska M, Devgan G, Zhao Y, Pestell R, Albanese C, Darnell JJ: Stat3 as an oncogene. Cell. 1999, 98: 295-303.View ArticlePubMed
- Buettner R, Mora L, Jove R: Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res. 2002, 8: 945-954.PubMed
- Song H, Wang R, Wang S, Lin J: A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci USA. 2005, 102: 4700-4705.PubMed CentralView ArticlePubMed
- Jing N, Tweardy DJ: Targeting Stat3 in cancer therapy. Anticancer Drugs. 2005, 16: 601-607.View ArticlePubMed
- Knowles MA: Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?. Carcinogenesis. 2006, 27: 361-373.View ArticlePubMed
- Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C: Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol. 2006, 24: 778-789.View ArticlePubMed
- Zieger K, Dyrskjot L, Wiuf C, Jensen JL, Andersen CL, Jensen KM, Orntoft TF: Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors. Clin Cancer Res. 2005, 11: 7709-7719.View ArticlePubMed
- Salz W, Eisenberg D, Plescia J, Garlick DS, Weiss RM, Wu XR, Sun TT, Altieri DC: A survivin gene signature predicts aggressive tumor behavior. Cancer Res. 2005, 65: 3531-3534.View ArticlePubMed
- Schultz IJ, Kiemeney LA, Witjes JA, Schalken JA, Willems JL, Swinkels DW, de Kok JB: Survivin mRNA expression is elevated in malignant urothelial cell carcinomas and predicts time to recurrence. Anticancer Res. 2003, 23: 3327-3331.PubMed
- Schaaf A, Sagi S, Langbein S, Trojan L, Alken P, Michel MS: Cytotoxicity of cisplatin in bladder cancer is significantly enhanced by application of bcl-2 antisense oligonucleotides. Urol Oncol. 2004, 22: 188-192.View ArticlePubMed
- Xia G, Kumar SR, Stein JP, Singh J, Krasnoperov V, Zhu S, Hassanieh L, Smith DL, Buscarini M, Broek D, Quinn DI, Weaver FA, Gill PS: EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival. Oncogene. 2006, 25: 769-780.View ArticlePubMed
- Korkolopoulou P, Lazaris A, Konstantinidou AE, Kavantzas N, Patsouris E, Christodoulou P, Thomas-Tsagli E, Davaris P: Differential expression of bcl-2 family proteins in bladder carcinomas. Relationship with apoptotic rate and survival. Eur Urol. 2002, 41: 274-283.View ArticlePubMed
- Swana HS, Grossman D, Anthony JN, Weiss RM, Altieri DC: Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med. 1999, 341: 452-453.View ArticlePubMed
- Itoh M, Murata T, Suzuki T, Shindoh M, Nakajima K, Imai K, Yoshida K: Requirement of STAT3 activation for maximal collagenase-1 (MMP-1) induction by epidermal growth factor and malignant characteristics in T24 bladder cancer cells. Oncogene. 2006, 25: 1195-1204.View ArticlePubMed
- Chen C-L, Loy A, Cen L, Chan C, Hsieh F-C, Cheng G, Wu B, Qualman SJ, Kunisada K, Yamauchi-Takihara K, Lin J: Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cells. BMC Cancer. 2007, 7: 111-PubMed CentralView ArticlePubMed
- Zhong Z, Wen Z, Darnell J: Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science. 1994, 264: 95-98.View ArticlePubMed
- Darnell JJ, Kerr I, Stark G: Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994, 264: 1415-1421.View ArticlePubMed
- Kunisada K, Tone E, Fujio Y, Matsui H, Yamauchi-Takihara K, Kishimoto T: Activation of gp130 transduces hypertrophic signals via STAT3 in cardiac myocytes. Circulation. 1998, 98: 346-352.View ArticlePubMed
- Funamoto M, Fujio Y, Kunisada K, Negoro S, Tone E, Osugi T, Hirota H, Izumi M, Yoshizaki K, Walsh K, Kishimoto T, Yamauchi-Takihara K: Signal transducer and activator of transcription 3 is required for glycoprotein 130-mediated induction of vascular endothelial growth factor in cardiac myocytes. J Biol Chem. 2000, 275: 10561-10566.View ArticlePubMed
- Hirano T, Ishihara K, Hibi M: Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene. 2000, 19: 2548-2556.View ArticlePubMed
- Levy DE, Darnell JE: Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol. 2002, 3: 651-662.View ArticlePubMed
- Takeda K, Noguchi K, Shi W, Tanaka T, Matsumoto M, Yoshida N, Kishimoto T, Akira S: Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci USA. 1997, 94: 3801-3804.PubMed CentralView ArticlePubMed
- Amin HM, McDonnell TJ, Ma Y, Lin Q, Fujio Y, Kunisada K, Leventaki V, Das P, Rassidakis GZ, Cutler C, Medeiros LJ, Lai R: Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma. Oncogene. 2004, 23: 5426-5434.View ArticlePubMed
- Cory S, Huang DC, Adams JM: The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene. 2003, 22: 8590-8607.View ArticlePubMed
- Adams JM, Cory S: Apoptosomes: engines for caspase activation. Curr Opin Cell Biol. 2002, 14: 715-720.View ArticlePubMed
- Cory S, Adams JM: The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer. 2002, 2: 647-656.View ArticlePubMed
- Ashkenazi A, Dixit VM: Apoptosis control by death and decoy receptors. Curr Opin Cell Biol. 1999, 11: 255-260.View ArticlePubMed
- Ivanov VN, Bhoumik A, Ronai Z: Death receptors and melanoma resistance to apoptosis. Oncogene. 2003, 22: 3152-3161.View ArticlePubMed
- Shivapurkar N, Toyooka S, Toyooka KO, Reddy J, Miyajima K, Suzuki M, Shigematsu H, Takahashi T, Parikh G, Pass HI, Chaudhary PM, Gazdar AF: Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types. Int J Cancer. 2004, 109: 786-792.View ArticlePubMed
- Butcher BA, Kim L, Panopoulos AD, Watowich SS, Murray PJ, Denkers EY: IL-10-independent STAT3 activation by Toxoplasma gondii mediates suppression of IL-12 and TNF-alpha in host macrophages. J Immunol. 2005, 174: 3148-3152.View ArticlePubMed
- Nishiki S, Hato F, Kamata N, Sakamoto E, Hasegawa T, Kimura-Eto A, Hino M, Kitagawa S: Selective activation of STAT3 in human monocytes stimulated by G-CSF: implication in inhibition of LPS-induced TNF-alpha production. Am J Physiol Cell Physiol. 2004, 286: C1302-1311.View ArticlePubMed
- Niu G, Shain KH, Huang M, Ravi R, Bedi A, Dalton WS, Jove R, Yu H: Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest. Cancer Res. 2001, 61: 3276-3280.PubMed
- Lee JI, Choi DY, Chung HS, Seo HG, Woo HJ, Choi BT, Choi YH: beta-lapachone induces growth inhibition and apoptosis in bladder cancer cells by modulation of Bcl-2 family and activation of caspases. Exp Oncol. 2006, 28: 30-35.PubMed
- Cho HJ, Kim JK, Kim KD, Yoon HK, Cho MY, Park YP, Jeon JH, Lee ES, Byun SS, Lim HM, Song EY, Lim JS, Yoon DY, Lee HG, Choe YK: Upregulation of Bcl-2 is associated with cisplatin-resistance via inhibition of Bax translocation in human bladder cancer cells. Cancer Lett. 2006, 237 (1): 56-66.View ArticlePubMed
- Calvin D, Nam S, Buettner R, Sekharam M, Torres-Roca J, Jove R: Inhibition of STAT3 activity with STAT3 antisense oligonucleotide (STAT3-ASO) enhances radiation-induced apoptosis in DU145 prostate cancer cells. Int J Radiat Oncol Biol Phys. 2003, 57: S297-View Article
- Lee SO, Lou W, Qureshi KM, Mehraein-Ghomi F, Trump DL, Gao AC: RNA interference targeting Stat3 inhibits growth and induces apoptosis of human prostate cancer cells. Prostate. 2004, 60: 303-309.View ArticlePubMed
- Turkson J, Zhang S, Mora LB, Burns A, Sebti S, Jove R: A novel platinum compound inhibits constitutive Stat3 signaling and induces cell cycle arrest and apoptosis of malignant cells. J Biol Chem. 2005, 280: 32979-32988.View ArticlePubMed
- Leong P, Andrews G, Johnson D, Dyer K, Xi S, Mai J, Robbins P, Gadiparthi S, Burke N, Watkins S, Grandis J: Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci USA. 2003, 100: 4138-4143.PubMed CentralView ArticlePubMed
- Wu R, Sun S, Steinberg BM: Requirement of STAT3 activation for differentiation of mucosal stratified squamous epithelium. Mol Med. 2003, 9: 77-84.PubMed CentralView ArticlePubMed
- Bhattacharya S, Ray RM, Johnson LR: STAT3-mediated transcription of Bcl-2, Mcl-1 and c-IAP2 prevents apoptosis in polyamine-depleted cells. Biochem J. 2005, 392: 335-344.PubMed CentralView ArticlePubMed
- Masuda M, Suzui M, Lim JT, Deguchi A, Soh JW, Weinstein IB: Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction. J Exp Ther Oncol. 2002, 2: 350-359.View ArticlePubMed
- Real PJ, Sierra A, De Juan A, Segovia JC, Lopez-Vega JM, Fernandez-Luna JL: Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene. 2002, 21: 7611-7618.View ArticlePubMed
- Burke WM, Jin X, Lin HJ, Huang M, Liu R, Reynolds RK, Lin J: Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells. Oncogene. 2001, 20: 7925-7934.View ArticlePubMed
- Hsieh FC, Cheng G, Lin J: Evaluation of potential Stat3-regulated genes in human breast cancer. Biochem Biophys Res Commun. 2005, 335: 292-299.View ArticlePubMed
- Chen C-L, Hsieh F-C, Brown J, Chan C, Wallaca JA, Cheng G, Hall BM, Lin J: Stat3 activation in human endometrial and cervical cancers. Br J Cancer. 2007, 96 (4): 591-599.PubMed CentralView ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.